Advertisement
Advertisement
U.S. markets close in 1 hour 2 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Lixiang Education Holding Co., Ltd. (LXEH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.92+0.12 (+1.22%)
As of 09:30AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close9.80
Open9.80
Bid8.95 x 800
Ask9.80 x 1100
Day's Range9.92 - 9.92
52 Week Range7.19 - 12.50
Volume4
Avg. Volume1,101
Market Cap132.267M
Beta (5Y Monthly)N/A
PE Ratio (TTM)20.45
EPS (TTM)0.49
Earnings DateApr 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-20% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for LXEH

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Lixiang Education Holding Co.,
    Analyst Report: I-MabI-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia.
    Rating
    Fair Value
    Economic Moat
    yesterdayMorningstar
View more
  • PR Newswire

    Lixiang Education Announces Strategic Investment in a Leading PRC Vocational Education Service Provider

    Lixiang Education Holding Co., Ltd. (NASDAQ: LXEH) (the "Company"), a prestigious private primary and secondary education service provider in China, today announced its entry into an investment cooperation agreement (the "Agreement"), through its wholly-owned PRC subsidiary, Zhejiang Lishui Mengxiang Education Development Co., Ltd. ("Mengxiang Education"), with Beijing Shangkun Education Technology Development Co., Ltd., a leading PRC vocational education service provider ("Beijing S.K."), and c

  • PR Newswire

    Lixiang Education Announces Appointment of Chief Financial Officer

    Lixiang Education Holding Co., Ltd. (NASDAQ: LXEH) (the "Company"), a prestigious private primary and secondary education service provider in China, today announced the appointment of Mr. Luoyuan Ye as the Chief Financial Officer ("CFO") of the Company, effective August 1, 2021. Mr. Ye will be primarily responsible for establishing, implementing and supervising the financial, accounting, audit and budgetary aspects of the operations of the Company. Former CFO Mr. Weijian Xu will remain with Comp

  • Simply Wall St.

    How Did Lixiang Education Holding Co., Ltd.'s (NASDAQ:LXEH) 9.1% ROE Fare Against The Industry?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Advertisement
Advertisement